Analysis of market price conjuncture for antibacterial drugs used in treatment of community acquired pneumonia
DOI:
https://doi.org/10.24959/uekj.17.11Keywords:
antibiotics, community acquired pneumonia, affordability indicator, solvency adequacy ratio, liquidity ratio of pricesAbstract
Community acquired pneumonia (CAP) belongs to life-threatening infections with high fatal consequences, characterized by lesions of the lower respiratory tract and involving the alveoli in inflammation. According to statistics pneumonia ranks first among all causes of death in infectious diseases, the sixth – among all causes of death and the fourth – leading cause of mortality in patients older than 65 years. In different countries the incidence of pneumonia ranges from 3.5 to 15 cases per 1 thousand of the population and the mortality rate – from 2.3 % to 25 %. Thus, given the high prevalence of pneumonia, the presence of complications, significant mortality of patients there are significant economic losses.
Aim is to give the scientific generalization of the results of studying the social and economic accessibility of antibiotics used to treat CAP.
Materials and methods. While making calculation and analysis of socio-economic accessibility indicators and liquidity ratios of prices analysis for antibacterial drugs in CAP treatment we mentioned the solvency ratio and availability factor (recommended by the Ministry of Health in CAP treatment).
Results. This article reflects the calculation results of social and economic accessibility indicators of antibacterial drugs (ABD), used to treat of CAP for the period 2014-2017. Liquidity ratios of prices of ABD for treatment of CAP, solvency adequacy ratio of the population and economic affordability indicator of these drugs (medicines) for the population were calculated. In the study of liquidity ratio of price (Cliq) found that during 2014-2017 there was an increase in price volatility from 22.6 % to 403 % on theUkrainepharmaceutical market, except ABD with international non-proprietary name (INN) amikacin. Solvency adequacy ratio (Ca.s) for all ABD during the period 2014-2017 has decreased, so accessibility of these drugs has increased except for ABD with INN ceftriaxone, cefuroxime and levofloxacin, which the solvency adequacy ratio has increased in 2017 compared to 2016 that is their accessibility during this period has decreased. The growth rate of wages was relatively higher rate of growth in prices for cefepime, a combination of amoxicillin and clavulanic acid, azithromycin, amikacin, amoxicillin, clarithromycin, cefuroxime and midecamycin. And for ceftriaxone and levofloxacin growth rate of prices higher than the growth rate of wages indicating the coefficient of economic affordability (D).
Conclusions. According to the study market price conjuncture of ABD for CAP treatment during the period 2014-2017 it was established a significant price fluctuations of ABD on the Ukraine pharmaceutical market, except price of ABD with INN midecamycin, which remained unchanged; it was observed fluctuations in accessibility of ABD for the population in solvency adequacy ratio regarding to certain drugs and periods of study; it revealed higher rate of wage growth than the growth rate of prices of researched ABD except ceftriaxone and levofloxacin, the rate of price growth exceeding the growth rate of wages.
References
Honcharov, K. A. (2015). Osoblyvosti likuvannia i diahnostyky nehospitalnoi pnevmonii virusno–bakterialnoi etiolohii netiazhkoho perebihu u viiskovosluzhbovtsiv Zbroinykh syl Ukrainy. Kyiv, 16.
Kotvitska, A. A., Korobova, E. S. (2016). Sotsialna farmatsiia v okhoroni zdorovia, 2 (4), 24–31.
Hrushkovska, T. D. (2011). Optymizatsiia likarskoho zabezpechennia khvorykh tuberkulozom. Lviv, 22.
Bieliaieva, O. I. (2015). Optymizatsiia likarskoho zabezpechennia ditei khvorykh na pnevmoniiu. Odesa, 23.
Nakaz MOZ Ukrayiny vid 19 bereznya 2007 r. № 128. Protokol nadannia medychnoi dopomohy khvorym na nehospitalnu ta nozokomialnu (hospitalnu) pnevmoniiu u doroslykh osib: etiolohiia, patohenez, klasyfikatsiia, diahnostyka, antybakterialna terapiia.
Nemchenko, A. S., Zharkova, S. O., Podhaina, M. V. (2012). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (24), 60–64.
Adonkina, V. Yu., Mishchenko, O. Ya. (2013). Klinichna farmatsiia – Clinical pharmacy, 17 (1), 8–11.
Ivko, T. I. (2016). Optymizatsiia likarskoho zabezpechennia khvorykh na tsukrovyi diabet 2 typu na osnovi marketynhovykh i farmakoekonomichnykh doslidzhen. Kyiv, 24.
Kotvytskaia, A. A., Korobova, E. S. (2015). Vestnik Tadzhykskoho natsyonalnoho universiteta, 1/2 (160), 270–276.
Ivko, T. I., Germaniuk, T. A. (2014). Rol ta mistse medytsyny u zabezpechenni zdorovia liudyny u suchasnomu suspilstvi. Odesa, 134–136.
Reiestr optovo–vidpusknykh tsin na likarski zasoby (2017). MOZ Ukrainy. Available at: http://www.moz. gov.ua/ua/portal/register_prices_drugs
Mnushko, Z. M., Timaniuk, I. V. (2007).Visnyk farmatsii – News of pharmacy, 1(49), 52–57.
Nemchenko, O. A., Tolochko, V. M. (2008). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 1 (1), 21–28.
Hudzenko, O. P., Kozytska, K. I. (2009). Ukrainskyi medychnyi almanakh, 12 (5), 63–66.
Nemchenko, A. S., Kosiachenko, K. L., Kubarieva, I. V. et al. (2008). Metodychni rekomendatsii z provedennia derzhavnoi ekspertyzy ta reiestratsii tsin na osnovni likarski zasoby. Kyiv, 22.
Hromovyk, B. P., Hasiuk, H. D., Levytska, O. R. (2004). Farmatsevtychnyi marketynh: teoretychni ta prykladni zasady. Vinnytsia: Nova Knyha, 464.
Mishchenko, O. Ya., Adonkina, V. Yu., Kuznietsov, I. Ye. (2013). Farmakoekonomika v Ukraini: stan ta perspektyvy rozvytku. Kharkiv: NUPh, 79–87.
Derzhavna sluzhba statystyky Ukrainy (2017). Available at: http://www.ukrstat.gov.ua
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
